On Jul 28, 2021 Ring Therapeutics closed a Series B round and raised $117,000,000 from Altitude Life Science Ventures, Flagship Pioneering, Invus, Partners Investment, T. Rowe Price, UPMC Enterprises, featuring lead investors Flagship Pioneering.
About the company: Ring Therapeutics is located at United States, North America.
“Pioneering a New Era of Gene Therapy. We are developing Anellovectorsâ¢, the first potentially redosable and targetable gene therapy platform, by harnessing the human commensal virome.”
Company website: www.ringtx.com/
